FOXO TECHNOLOGIES INC. (FOXO) Operating Margin
- Operating margin · 12 months: Value -4.91%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -4.91% | Operating income / revenue. Period ending 2026-06-30. $-877.76K ÷ $17.86M × 100 ≈ -4.91% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -877.76K USD | Operating Income (Loss) |
| Revenue | 17.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 171.56K USD | Research and Development Expense |
| Selling, general and administration | 11.53M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-877.76K | $17.86M | (m) | $171.56K | $11.53M | -4.91% |
| 2026-03-31 | $-9.06M | $18.37M | (m) | $188.05K | $11.47M | -49.33% |
| 2025-12-31 | $-10.33M | $16.37M | (m) | $182.50K | $11.36M | -63.11% |
| 2025-09-30 | $-5.83M | $14.76M | (m) | $147.28K | $10.89M | -39.49% |
| 2025-06-30 | $-5.97M | $12.41M | (m) | $113.99K | $10.14M | -48.15% |
| 2025-03-31 | $-8.13M | $7.21M | (m) | $176.91K | $9.00M | -112.70% |
| 2024-12-31 | $-7.76M | $4.05M | (m) | $312.27K | $7.23M | -191.58% |
| 2024-09-30 | $-7.46M | $1.34M | (m) | $288.00K | $8.54M | -556.08% |
| 2024-06-30 | $-9.96M | $155.00K | (m) | $528.00K | $11.53M | -6425.16% |
| 2024-03-31 | $-15.97M | $139.00K | (m) | $757.00K | $14.05M | -11492.81% |
| 2023-12-31 | $-22.19M | $145.00K | (m) | $901.00K | $19.40M | -15302.07% |
| 2023-09-30 | $-39.37M | $453.00K | (m) | $1.81M | $25.01M | -8689.85% |
| 2023-06-30 | $-44.67M | $457.00K | (m) | $2.09M | $28.56M | -9774.84% |
| 2023-03-31 | $-43.00M | $484.00K | (m) | $2.75M | $29.53M | -8883.47% |
| 2022-12-31 | $-40.17M | $511.00K | $344.00K | $3.05M | $27.20M | -7860.47% |
| 2022-09-30 | $-13.69M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-5.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-4.27M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-2.08M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |